4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics reported Q2 2026 results highlighted by late-stage clinical progress and a strengthened balance sheet. Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, which, together with expected Otsuka collaboration payments, is estimated to fund operations into the second half of 2028. The company also entered a strategic credit facility with Hercules Capital for up to $200 million, drawing $20 million at closing.
Collaboration and license revenue was $3.8 million in Q2 2026, while research and development expenses rose to $68.3 million and general and administrative expenses to $12.5 million. Net loss was $72.9 million, or $1.04 per share. Clinically, enrollment was completed in both 4FRONT-1 and 4FRONT-2 Phase 3 trials of 4D-150 for wet AMD, with topline data expected in 2027, and a Phase 3 DME trial is planned to start in Q3 2026. Two-year PRISM Phase 2b data showed sustained visual outcomes and a 78–87% reduction in treatment burden versus projected aflibercept dosing, with a favorable safety profile.
4D Molecular Therapeutics, Inc. director and officer David Kirn sold 26,842 shares of common stock on August 4, 2026 at a weighted average price of $10.2301 per share. The sale was executed in multiple trades between $10.07 and $10.42 pursuant to a 10b5-1 trading plan adopted January 9, 2026. After this transaction, he directly owns 844,895 common shares.
The issuer of FDMT Class A Common Stock has a planned sale of up to 26,842 shares, to be executed through Goldman Sachs & Co. LLC on the NASD on or about August 4, 2026, with an aggregate market value of $275,398.92. The shares were acquired from the issuer in a private transaction on December 15, 2020.
Over the prior three months, shareholder David Kirn reported multiple sales of Class A Common Stock, including 114,746 shares for $1,200,851.31 on June 22, 2026, 42,608 shares for $548,177.48 on July 9, 2026, and several smaller transactions on June 1, July 10, and August 3, 2026.
4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn sold 12,415 shares of common stock on August 3, 2026 at a weighted average price of $10.0461 per share, pursuant to a 10b5-1 trading plan adopted January 9, 2026, and now directly holds 871,737 shares.
FDMT shareholder David Kirn has filed a notice of proposed sale of 12,415 shares of Class A Common Stock, to be sold through Goldman Sachs & Co. LLC on or after August 3, 2026 on the NASD market. The proposed sale has an aggregate market value of $125,267.35. The issuer reports 52,276,254 Class A Common shares outstanding.
The shares to be sold were acquired from the issuer in a private transaction dated December 15, 2020. Over the past three months, David Kirn has sold Class A Common Stock in several transactions, including 1,922 shares for $19,257.86 on June 1, 2026, 114,746 shares for $1,200,851.31 on June 22, 2026, 42,608 shares for $548,177.48 on July 9, 2026, and 15,725 shares for $189,233.08 on July 10, 2026.
4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating its product candidate 4D-150 in a broad wet age-related macular degeneration population, based on a data cutoff of May 18, 2026. The disclosure highlights trial and patient cohort overview information, Phase 2b efficacy results through 2 years, and safety data for the selected Phase 3 dose across the overall PRISM Phase 1/2a and 2b clinical trial population of 71 patients.
The company explains that statements about the therapeutic potential, treatment-burden reduction, durability and success of clinical trials for 4D-150 are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties described in its most recent quarterly report filed on May 7, 2026, and the company disclaims any obligation to update forward-looking statements.
4D Molecular Therapeutics, Inc. director and officer David Kirn reported three open-market sales totaling 58,333 shares of common stock on July 9–10, 2026, at weighted average prices of $12.8656, $12.8355 and $12.0107 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 884,152 shares of FDMT common stock.
FDMT received a Form 144 notice covering a proposed sale of 15,725 shares of Class A Common stock by Goldman Sachs & Co. LLC. The shares were acquired from the issuer in a private transaction on 12/15/2020, and the planned sale date is 07/10/2026.
The notice cites an aggregate market value of $193,574.75 for the shares to be sold, with 52,276,254 shares of Class A Common stated as outstanding. It also lists prior sales by David Kirn over the past three months, including 1,922 shares on 06/01/2026, 114,746 shares on 06/22/2026, and 42,608 shares on 07/09/2026.
David Kirn reported sales of Class A Common shares. On 06/01/2026 he sold 1,922 shares for $19,257.86. On 06/22/2026 he sold 114,746 shares for $1,200,851.31. The shares were acquired from the issuer in a private transaction on 12/15/2020.
4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he sold 6,566 shares of common stock at $14.00 per share in an open-market transaction made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026.
On the same date, he exercised stock options covering 5,752 shares at an exercise price of $6.49 per share and 814 shares at $4.14 per share, converting these derivative awards into common shares. The options exercised were from grants originally scheduled to vest monthly over four years and carried expiration dates in 2032 and 2035.